American Association of Clinical Endocrinology

08/07/2026

With obesity affecting an estimated 90 million people in the United States, GLP-1 receptor agonists have emerged as highly effective pharmacologic interventions for obesity and related cardiometabolic comorbidities. These and other obesity pharmacotherapies become increasingly prescribed, clinicians need practical, evidence-based tools to guide nutritional counseling. Dietary quality becomes especially critical when caloric intake is reduced — nutritional needs must still be fully met. Read more and download our quick-reference clinician guide: https://pro.aace.com/nutritional-considerations-for-patients-on-obesity-medications

08/07/2026

Although use of SGLT2 inhibitors and GLP-1 receptor agonists increased substantially from 2014 to 2024, Black patients, publicly insured patients, and those living in more socially vulnerable neighborhoods remained less likely to receive these guideline-recommended therapies. Read more: https://www.endocrinologydiabetes.org/article/S3050-9157(26)00072-X/fulltext

08/07/2026

In an AACE Endocrine AI video, Johnson Thomas, MD, FACE, FEAA, demonstrates how clinicians can use AI tools to build an osteoporosis-focused clinical infographic on screening, treatment, and monitoring.

Dr. Thomas walks through a practical example using a detailed prompt and compares outputs from ChatGPT, Claude, and Gemini, showing how AI-generated materials can vary in style, level of detail, and usefulness for clinical education.

Key takeaways include writing specific prompts, providing a visual template when possible, and verifying all clinical information against current guidelines before sharing.

Watch now:

News Technology Predictive Risk Models Ethics, Regulation, and Responsible Use Diagnostics & Imaging How to build infographics with AI June 10, 2026 By AACE Endocrine AI staff 1 min watch Share Share via Email Share on Facebook Share on LinkedIn Share on Twitter Please enable JavaScript or upgrade t...

08/06/2026

A decades-long study shows that excess weight acts as a cumulative exposure shaping lifelong metabolic health, with rapid BMI gain in childhood strongly predicting later-life clusters of hypertension, diabetes, dyslipidemia, and organ dysfunction. AACE President Dace L. Trence, MD, MACE, praised the 36-year follow-up and robust cohort and stressed the importance of early weight-control strategies, even during ages 6 to 18 — typically an age range in which we don’t focus on weight unless obesity or morbid obesity is present. Read more: https://www.medscape.com/viewarticle/rapid-childhood-weight-gain-predicts-later-life-metabolic-2026a1000pme?form=fpf

Followed over decades, a cohort of children with faster BMI accumulation was more likely to develop clusters of metabolic diseases in adulthood, with the highest risk found in men.

08/06/2026

These findings underscore primary care as the most impactful setting for targeted interventions to improve thyroid monitoring and optimize disease control. Read more: https://www.endocrinologydiabetes.org/article/S3050-9157(26)00080-9/fulltext

08/06/2026

In a new evaluation of AI tools, researchers found that general-purpose LLMs performed as well as or better than commercial clinical AI platforms across standardized benchmarks and blinded clinician review of real-world physician queries.

The authors described the results as a snapshot of a rapidly evolving landscape and called for independent evaluation before clinical implementation. Read more: https://aaceendocrine.ai/articles/2026/06/general-purpose-llms-outperform-commercial-medical-ai-tools/

News Research Research and Evidence General-purpose LLMs outperform commercial medical AI tools Results represent “a snapshot of a rapidly evolving landscape." June 25, 2026 By Matthew Solan 4 min read Share Share via Email Share on Facebook Share on LinkedIn Share on Twitter As artificial intelli...

08/05/2026

Join endocrinologist Elizabeth Bauer, MD, FACP, FACE, DABOM, as she speaks with Michelle about her experience living with obesity, including the challenges, stigma, and turning points that shaped her path. Together, they explore the AACE Journey for Patients With Obesity, as Michelle shares which parts she found most helpful for understanding obesity as a chronic disease and navigating next steps. Don’t miss this inspiring discussion, brought to you with the support of Boehringer-Ingelheim, Lilly, Novo Nordisk, and Amgen.

https://www.youtube.com/watch?v=LHg2CdM6K0U

08/05/2026

Dyslipidemia is a major contributor to cardiovascular disease, yet many patients remain undermanaged due to evolving guidelines and care complexities.

Health care professionals need targeted education to improve risk assessment, apply evidence-based therapies, and personalized treatment.

This program addresses these gaps, helping clinicians optimize lipid management and improve cardiovascular outcomes.

Learn more about the AACE Certificate: Dyslipidemia and Lipids Management: https://pro.aace.com/education-and-event/product/aace-certificate-dyslipidemia-and-lipids-management

08/05/2026

Automated insulin delivery systems increased time in range and reduced hyperglycemia in cystic fibrosis related diabetes without increasing hypoglycemia, consistent with type 1 and type 2 diabetes studies. Read more: https://www.endocrinepractice.org/article/S1530-891X(26)00921-3/fulltext

08/04/2026

Register for our free webinar series- The Metabolic Paradox: Understanding the Interplay Between Obesity and MASLD/MASH. Learn about the latest treatment guidelines and algorithms, emerging pharmacotherapies, and evidence-based approaches.

This complimentary educational series has been designed for the full endocrine care team, including endocrinologists, primary care physicians, and allied health professionals like nurses and physician assistants. Each module within this course is intended to support the endocrine care team in enhanc...